治疗类风湿性关节炎的选择性Janus激酶3抑制药peficitinib

Janus Kinase 3-Selective Inhibitor Peficitinib for the Treatment of Rheumatoid Arthritis

Peficitinib是日本安斯泰来制药公司开发的口服小分子选择性Janus激酶3抑制药,于2019年3月在日本获准用于治疗对传统药物反应不佳的类风湿性关节炎成年患者。本文主要描述该药的药效学、药动学、临床疗效和安全性等信息,旨在为临床医生和患者提供参考。

Peficitinib is an orally administered small Janus kinase 3-selective inhibitor developed by Japanese Astellas Pharma.The novel therapeutic agent received its first global approval in March 2019 in Japan for the treatment of rheumatoid arthritis in adult patients with inadequate response to the conventional therapies.The article summarized its information about pharmacodynamics,pharmacokinetics,clinical efficacy and safety to provide good reference for clinicians and patients.